US Tissue Diagnostics Market Size, Trends and Insights By Technology (In Situ Hybridization, Immunohistochemistry, Digital Pathology and workflow, Primary and Special Staining, Anatomic Pathology), By Application (Prostate Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Other Cancer), By End Users (Research Laboratories, Hospitals, Contract Research Organizations (CROs), Pharmaceutical Organizations) and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | USA |
| Largest Market: | USA |
Major Players
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratorie, Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Others
Reports Description
As per the current market research conducted by CMI Team, the US Tissue Diagnostics Market is expected to record a CAGR of 6.8% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD 2,017.2 Million. By 2032, the valuation is anticipated to reach USD 3,655.5 Million.
The US Tissue Diagnostics Market encompasses the industry involved in the precise examination and analysis of tissue samples for accurate disease detection and diagnosis. Key players, including Roche Diagnostics and Thermo Fisher Scientific, contribute to advancements through technologies like digital pathology and molecular diagnostics.
Trends driving the market include a focus on personalized medicine, integration of artificial intelligence, and an increasing emphasis on early disease detection. With a growing aging population and continuous research investments, the market plays a pivotal role in enhancing healthcare outcomes by offering sophisticated diagnostic solutions tailored to individual patient needs.
US Tissue Diagnostics Market – Significant Growth Factors
The US Tissue Diagnostics Market presents significant growth opportunities due to several factors:
- Technological Advancements: Continuous innovations, such as digital pathology and molecular diagnostics, drive the US Tissue Diagnostics Market. These advancements enhance diagnostic precision, improve workflow efficiency, and contribute to the overall growth of the market.
- Rising Incidence of Chronic Diseases: The increasing prevalence of chronic diseases, particularly cancer, is a major driver. Tissue diagnostics play a crucial role in early detection, precise diagnosis, and personalized treatment planning.
- Aging Population: The demographic shift towards an aging population in the US increases the incidence of age-related diseases, fostering the demand for tissue diagnostics and supporting market growth.
- Government Initiatives and Healthcare Investments: Supportive government initiatives, increased investments in healthcare infrastructure, and research funding create a favorable environment for market growth, facilitating advancements in tissue diagnostics technologies and services.
- Integration of Artificial Intelligence (AI): The incorporation of AI presents a significant opportunity. AI applications in tissue diagnostics can enhance data analysis, improve diagnostic accuracy, and streamline pathology workflows, fostering innovation and growth.
- Collaborations and Research Partnerships: Opportunities lie in collaborations between industry players, research institutions, and healthcare providers. Strategic partnerships can lead to the development of novel diagnostic solutions, addressing unmet needs and expanding the market’s capabilities.
US Tissue Diagnostics Market – Mergers and Acquisitions
The US Tissue Diagnostics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the US Tissue Diagnostics Market include:
- In 2023, Agilent Technologies, Inc. partnered with Akoya Biosciences, Inc. to co-develop multiplex immunohistochemistry (IHC) diagnostic solutions. This collaboration aims to commercialize workflow solutions for multiplex assays in tissue analysis, offering an advanced multiplex IHC solution for biomarker clinical research, leveraging the capabilities of digital pathology.
- In 2022, F. Hoffmann-La Roche Ltd, headquartered in Switzerland, obtained FDA approval for the label expansion of the VENTANA MMR RxDx Panel. This approval signifies an enhanced capability for the panel in identifying mismatch repair deficiencies, contributing to advanced diagnostics and personalized treatment strategies in the US.
- In 2022, F. Hoffmann-La Roche Ltd obtained FDA approval for its PATHWAY anti-HER2/neu (485) Rabbit Monoclonal Primary Antibody. This antibody serves as a companion diagnostic test, aiding in the identification of metastatic breast cancer patients exhibiting low HER2 expression. The approval enhances precision in determining suitable treatment strategies for this specific patient population.
- In 2021, Roche introduced the DISCOVERY Green HRP Chromogen Detection Kit, aiming to broaden immunohistochemistry multiplexing capabilities in cancer research. This kit enhances the detection of multiple biomarkers simultaneously, facilitating more comprehensive and detailed analysis in the field of cancer diagnostics and research.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the US Tissue Diagnostics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| US Tissue Diagnostics Market | Animal Biotechnology Market | Optical Genome Mapping Market |
| CAGR 6.8% (Approx) | CAGR 8.5% (Approx) | CAGR 17.5% (Approx) |
| USD 3,655.5 Million by 2032 | USD 68.2 Billion by 2032 | USD 329.2 Million by 2032 |
US Tissue Diagnostics Market – Significant Threats
The US Tissue Diagnostics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Stringent Regulatory Environment: The US Tissue Diagnostics Market faces threats from evolving and stringent regulatory requirements. Compliance challenges can increase operational costs and pose obstacles to obtaining timely product approvals, affecting market entry and growth.
- Data Security and Privacy Concerns: The increasing reliance on digital pathology and electronic health records introduces potential threats related to data security and patient privacy. Cybersecurity risks and data breaches may undermine confidence in tissue diagnostics technologies, impacting market acceptance.
- High Implementation Costs: The initial costs associated with implementing advanced tissue diagnostic technologies can act as a significant barrier. This financial challenge may limit adoption, particularly for smaller healthcare facilities, hindering market growth.
- Competition from Alternative Diagnostic Methods: Emerging alternatives such as liquid biopsies and molecular diagnostics pose a competitive threat. These alternatives offer less invasive approaches, potentially diverting demand away from traditional tissue-based diagnostic methods and affecting market share.
- Supply Chain Disruptions: The US tissue diagnostics market’s reliance on a complex global supply chain for reagents, equipment, and consumables makes it susceptible to disruptions. Events like geopolitical tensions, natural disasters, or health crises can lead to shortages and impact the availability of essential components.
Category-Wise Insights
By Technology:
- In Situ Hybridization (ISH): In Situ, Hybridization in the US Tissue Diagnostics Market involves localizing nucleic acid sequences in tissues. Trends include an increased application in molecular diagnostics, aiding in the precise identification of genetic abnormalities and biomarkers, and contributing to personalized medicine.
- Immunohistochemistry (IHC): Immunohistochemistry employs antibodies to detect proteins in tissues. In the US Tissue Diagnostics Market, trends involve advanced antibody development, expanding diagnostic applications, and a growing emphasis on multiplex staining for comprehensive analysis.
- Digital Pathology and Workflow: Digital Pathology integrates advanced imaging for efficient pathology workflows. In the US Tissue Diagnostics Market, trends include widespread adoption of remote diagnostics, AI integration for image analysis, and enhanced collaboration among pathologists for improved patient care.
- Primary and Special Staining: Primary and Special Staining in the US Tissue Diagnostics Market involves coloring tissues for microscopic examination. Trends include automation for standardized staining, rapid turnaround times, and customization to meet diverse diagnostic needs.
- Anatomic Pathology: Anatomic Pathology in the US Tissue Diagnostics Market encompasses the study of tissues for disease diagnosis. Trends involve an increased focus on personalized medicine, molecular diagnostics integration, and advancements in techniques for more precise disease characterization.
By Application
- Prostate Cancer: Tissue diagnostics for prostate cancer involve the examination of prostate tissues. Trends include an increasing focus on personalized treatment approaches, the adoption of biomarker-driven diagnostics, and advancements in imaging technologies for accurate staging.
- Breast Cancer: Breast cancer tissue diagnostics assess breast tissue abnormalities. Trends include a surge in HER2 testing, expanding applications of liquid biopsies, and a growing emphasis on molecular profiling for tailored therapeutic strategies.
- Lung Cancer: Tissue diagnostics for lung cancer analyze lung tissues for abnormalities. Trends involve a rising adoption of companion diagnostics, utilization of minimally invasive procedures, and the integration of immunohistochemistry for comprehensive tumor characterization.
- Gastric Cancer: Tissue diagnostics for gastric cancer examine stomach tissues. Trends encompass an increasing role of molecular testing for targeted therapies, advancements in endoscopic biopsy techniques, and a focus on identifying specific biomarkers for prognosis and treatment planning.
- Other Cancer: Tissue diagnostics for various cancers beyond the mentioned types. Trends include a growing adoption of next-generation sequencing for comprehensive genomic profiling and an increased focus on multiplex immunohistochemistry for a detailed understanding of tumor biology and heterogeneity.
By End User
- Research Laboratories: Research laboratories in the US Tissue Diagnostics Market conduct detailed studies for diagnostic advancements. Trends include a shift towards molecular diagnostics and increased utilization of digital pathology to enhance research precision and efficiency.
- Hospitals: Hospitals in the US Tissue Diagnostics Market provide vital diagnostic services. Trends involve digital pathology integration, personalized medicine adoption, and an emphasis on point-of-care diagnostics for enhanced patient care.
- Contract Research Organizations (CROs): Contract Research Organizations (CROs) play a crucial role in clinical research. Trends include rising demand for multiplex assays, advanced imaging technologies, and customized diagnostic solutions for research studies.
- Pharmaceutical Organizations: Pharmaceutical organizations leverage tissue diagnostics for drug development. Trends include a focus on companion diagnostics, biomarker identification for targeted therapies, and collaborations with diagnostic companies to streamline the drug development process.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 2,017.2 Million |
| Projected Market Size in 2032 | USD 3,655.5 Million |
| Market Size in 2022 | USD 1,903.5 Million |
| CAGR Growth Rate | 6.8% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Technology, Application, End Users and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Country Scope | US |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Competitive Landscape – US Tissue Diagnostics Market
The US Tissue Diagnostics Market is highly competitive, with a large number of manufacturers and retailers operating. Some of the key players in the market include:
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratorie, Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Becto, Dickinson and Company (BD)
- Sysmex Corporation
- Illumina Inc.
- PerkinElmer Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Hologic Inc.
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
Emerging entrants like Guardant Health and Foundation Medicine are pioneers in adopting innovations such as liquid biopsies and advanced sequencing technologies, entering the US Tissue Diagnostics Market with a focus on precision medicine and molecular diagnostics, contributing to market dynamism and evolution.
Established leaders, including Roche Diagnostics, Thermo Fisher Scientific, and Danaher Corporation, dominate the US Tissue Diagnostics Market. Their market dominance is rooted in extensive R&D, diverse product portfolios, strategic acquisitions, and strong collaborations, ensuring a comprehensive suite of tissue diagnostic solutions and reinforcing their market leadership.
The US Tissue Diagnostics Market is segmented as follows:
By Technology
- In Situ Hybridization
- Consumables
- Instruments
- Software
- Immunohistochemistry
- Instruments
- Slide Staining Systems
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Other Products
- Consumables
- Antibodies
- Reagents
- Kits
- Instruments
- Digital Pathology and workflow
- Whole Slide Imaging
- Image Analysis Informatics
- Information Management System Storage & Communication
- Primary and Special Staining
- Anatomic Pathology
- Instruments
- Microtomes & Cryostat Microtomes
- Tissue Processors
- Automatic Strainers
- Other Products
- Consumables
- Reagents & Antibodies
- Probes & Kits
- Others
By Application
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Gastric Cancer
- Other Cancer
By End Users
- Research Laboratories
- Hospitals
- Contract Research Organizations (CROs)
- Pharmaceutical Organizations
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 US Tissue Diagnostics Market, (2024 – 2033) (USD Million)
- 2.2 US Tissue Diagnostics Market: snapshot
- Chapter 3. US Tissue Diagnostics Market – Industry Analysis
- 3.1 US Tissue Diagnostics Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Technological Advancements
- 3.2.2 Increasing Incidence of Chronic Diseases
- 3.2.3 Aging Population
- 3.2.4 Rising Awareness and Patient Demand
- 3.2.5 Telehealth Integration
- 3.2.6 Collaboration and Research Opportunities
- 3.2.7 Government Initiatives and Funding.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End Users
- Chapter 4. US Tissue Diagnostics Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 US Tissue Diagnostics Market: Company Market Share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. US Tissue Diagnostics Market – Technology Analysis
- 5.1 US Tissue Diagnostics Market Overview: By Technology
- 5.1.1 US Tissue Diagnostics Market Share, By Technology, 2022 and – 2033
- 5.2 In Situ Hybridization
- 5.2.1 US Tissue Diagnostics Market by In Situ Hybridization, 2024 – 2033 (USD Million)
- 5.3 Consumables
- 5.3.1 US Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Million)
- 5.4 Instruments
- 5.4.1 US Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Million)
- 5.5 Software
- 5.5.1 US Tissue Diagnostics Market by Software, 2024 – 2033 (USD Million)
- 5.6 Immunohistochemistry
- 5.6.1 US Tissue Diagnostics Market by Immunohistochemistry, 2024 – 2033 (USD Million)
- 5.7 Instruments
- 5.7.1 US Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Million)
- 5.8 Slide Staining Systems
- 5.8.1 US Tissue Diagnostics Market by Slide Staining Systems, 2024 – 2033 (USD Million)
- 5.9 Tissue Microarrays
- 5.9.1 US Tissue Diagnostics Market by Tissue Microarrays, 2024 – 2033 (USD Million)
- 5.10 Tissue Processing Systems
- 5.10.1 US Tissue Diagnostics Market by Tissue Processing Systems, 2024 – 2033 (USD Million)
- 5.11 Slide Scanners
- 5.11.1 US Tissue Diagnostics Market by Slide Scanners, 2024 – 2033 (USD Million)
- 5.12 Other Products
- 5.12.1 US Tissue Diagnostics Market by Other Products, 2024 – 2033 (USD Million)
- 5.13 Consumables
- 5.13.1 US Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Million)
- 5.14 Antibodies
- 5.14.1 US Tissue Diagnostics Market by Antibodies, 2024 – 2033 (USD Million)
- 5.15 Reagents
- 5.15.1 US Tissue Diagnostics Market by Reagents, 2024 – 2033 (USD Million)
- 5.16 Kits
- 5.16.1 US Tissue Diagnostics Market by Kits, 2024 – 2033 (USD Million)
- 5.17 Digital Pathology and Workflow
- 5.17.1 US Tissue Diagnostics Market by Digital Pathology and Workflow, 2024 – 2033 (USD Million)
- 5.18 Whole Slide Imaging
- 5.18.1 US Tissue Diagnostics Market by Whole Slide Imaging, 2024 – 2033 (USD Million)
- 5.19 Image Analysis Informatics
- 5.19.1 US Tissue Diagnostics Market by Image Analysis Informatics, 2024 – 2033 (USD Million)
- 5.20 Information Management System Storage & Communication
- 5.20.1 US Tissue Diagnostics Market by Information Management System Storage & Communication, 2024 – 2033 (USD Million)
- 5.21 Primary and Special Staining
- 5.21.1 US Tissue Diagnostics Market by Primary and Special Staining, 2024 – 2033 (USD Million)
- 5.22 Anatomic Pathology
- 5.22.1 US Tissue Diagnostics Market by Anatomic Pathology, 2024 – 2033 (USD Million)
- 5.23 Instruments
- 5.23.1 US Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Million)
- 5.24 Microtomes & Cryostat Microtomes
- 5.24.1 US Tissue Diagnostics Market by Microtomes & Cryostat Microtomes, 2024 – 2033 (USD Million)
- 5.25 Tissue Processors
- 5.25.1 US Tissue Diagnostics Market by Tissue Processors, 2024 – 2033 (USD Million)
- 5.26 Automatic Strainers
- 5.26.1 US Tissue Diagnostics Market by Automatic Strainers, 2024 – 2033 (USD Million)
- 5.27 Other Products
- 5.27.1 US Tissue Diagnostics Market by Other Products, 2024 – 2033 (USD Million)
- 5.28 Consumables
- 5.28.1 US Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Million)
- 5.29 Reagents & Antibodies
- 5.29.1 US Tissue Diagnostics Market by Reagents & Antibodies, 2024 – 2033 (USD Million)
- 5.30 Probes & Kits
- 5.30.1 US Tissue Diagnostics Market by Probes & Kits, 2024 – 2033 (USD Million)
- 5.31 Others
- 5.31.1 US Tissue Diagnostics Market by Others, 2024 – 2033 (USD Million)
- 5.1 US Tissue Diagnostics Market Overview: By Technology
- Chapter 6. US Tissue Diagnostics Market – Application Analysis
- 6.1 US Tissue Diagnostics Market Overview: By Application
- 6.1.1 US Tissue Diagnostics Market Share, By Application, 2022 and – 2033
- 6.2 Prostate Cancer
- 6.2.1 US Tissue Diagnostics Market by Prostate Cancer, 2024 – 2033 (USD Million)
- 6.3 Breast Cancer
- 6.3.1 US Tissue Diagnostics Market by Breast Cancer, 2024 – 2033 (USD Million)
- 6.4 Lung Cancer
- 6.4.1 US Tissue Diagnostics Market by Lung Cancer, 2024 – 2033 (USD Million)
- 6.5 Gastric Cancer
- 6.5.1 US Tissue Diagnostics Market by Gastric Cancer, 2024 – 2033 (USD Million)
- 6.6 Other Cancer
- 6.6.1 US Tissue Diagnostics Market by Other Cancer, 2024 – 2033 (USD Million)
- 6.1 US Tissue Diagnostics Market Overview: By Application
- Chapter 7. US Tissue Diagnostics Market – End Users Analysis
- 7.1 US Tissue Diagnostics Market Overview: By End Users
- 7.1.1 US Tissue Diagnostics Market Share, By End Users, 2022 and – 2033
- 7.2 Research Laboratories
- 7.2.1 US Tissue Diagnostics Market by Research Laboratories, 2024 – 2033 (USD Million)
- 7.3 Hospitals
- 7.3.1 US Tissue Diagnostics Market by Hospitals, 2024 – 2033 (USD Million)
- 7.4 Contract Research Organizations (CROs)
- 7.4.1 US Tissue Diagnostics Market by Contract Research Organizations (CROs), 2024 – 2033 (USD Million)
- 7.5 Pharmaceutical Organizations
- 7.5.1 US Tissue Diagnostics Market by Pharmaceutical Organizations, 2024 – 2033 (USD Million)
- 7.1 US Tissue Diagnostics Market Overview: By End Users
- Chapter 8. US Tissue Diagnostics Market – Regional Analysis
- 8.1 US Tissue Diagnostics Market Regional Overview
- 8.2 US Tissue Diagnostics Market Share, by Region, 2022 & – 2033 (USD Million)
- Chapter 9. Company Profiles
- 9.1 Danaher Corporation
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Agilent Technologies Inc.
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Bio-Rad Laboratorie Inc.
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Siemens Healthineers
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Leica Biosystems Nussloch GmbH
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Becto Dickinson and Company (BD)
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Sysmex Corporation
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Illumina Inc.
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 PerkinElmer Inc.
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Merck KGaA
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Cell Signaling Technology Inc.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 Hologic Inc.
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Roche Diagnostics Corporation
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 Thermo Fisher Scientific Inc.
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.15 Abbott Laboratories
- 9.15.1 Overview
- 9.15.2 Financials
- 9.15.3 Product Portfolio
- 9.15.4 Business Strategy
- 9.15.5 Recent Developments
- 9.16 Others.
- 9.16.1 Overview
- 9.16.2 Financials
- 9.16.3 Product Portfolio
- 9.16.4 Business Strategy
- 9.16.5 Recent Developments
- 9.1 Danaher Corporation
List Of Figures
Figures No 1 to 50
List Of Tables
Tables No 1 to 2
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2032
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratorie, Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Becto, Dickinson and Company (BD)
- Sysmex Corporation
- Illumina Inc.
- PerkinElmer Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Hologic Inc.
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Others
FAQs
The key factors driving the Market are Technological Advancements, Rising Incidence of Chronic Diseases, Aging Population, Government Initiatives and Healthcare Investments, Integration of Artificial Intelligence (AI) And Collaborations and Research Partnerships.
The “Prostate Cancer” had the largest share in the global market for US Tissue Diagnostics.
The “In Situ Hybridization” category dominated the market in 2022.
The key players in the market are Danaher Corporation, Agilent Technologies Inc., Bio-Rad Laboratorie, Inc., Siemens Healthineers, Leica Biosystems Nussloch GmbH , Becto, Dickinson and Company (BD), Sysmex Corporation, Illumina Inc., PerkinElmer Inc., Merck KGaA, Cell Signaling Technology Inc., Hologic Inc., Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Others.
The global market is projected to grow at a CAGR of 6.8% during the forecast period, 2023-2032.
The US Tissue Diagnostics Market size was valued at USD 2,017.2 Million in 2023.